signific
outstand
problem
clinic
manag
asthma
failur
prevent
andor
effici
treat
asthma
exacerb
associ
signific
morbid
risk
death
high
treatment
cost
gener
asthma
exacerb
consid
increas
patient
asthma
symptom
increasingli
impair
lung
function
requir
increas
medic
unschedul
visit
physician
hospit
singl
asthma
exacerb
requir
extra
medic
possibl
emerg
treatment
hospit
increas
annual
treatment
cost
threefold
recurr
asthma
exacerb
lead
progress
declin
lung
function
risk
exacerb
doubl
children
one
previou
year
rare
distinct
phenotyp
asthma
exacerb
character
develop
sudden
sever
asthma
symptom
otherwis
mild
asymptomat
asthmat
subject
may
trigger
allergen
drug
eg
aspirin
food
air
pollut
occup
agent
viru
infect
mani
case
unknown
unidentifi
trigger
propos
within
group
patient
recurr
exacerb
detail
phenotyp
term
clinic
symptom
lung
function
inflammatori
biomark
warrant
signific
unmet
need
identifi
character
factor
increas
risk
asthma
exacerb
therapeut
prevent
option
reduc
risk
patient
sever
asthma
high
morbid
mortal
often
requir
hospit
expens
treat
divers
clinic
profil
probabl
reflect
divers
diseas
mechan
mani
standard
treatment
suffici
effect
sever
asthma
compris
highli
heterogen
group
patient
defin
variou
way
publish
literatur
nation
intern
guidelin
consensu
emerg
patient
consid
asthma
persist
symptom
recurr
exacerb
despit
prescrib
therapi
highest
step
guidelin
pharmacolog
manag
howev
worth
emphas
guidelin
also
make
clear
asthma
multifactori
issu
incorrect
diagnosi
comorbid
condit
nonadher
prescrib
medic
psychosoci
morbid
number
factor
discuss
later
manuscript
major
caus
difficult
asthma
patient
consid
sever
asthma
resist
current
avail
therapi
follow
detail
analysi
appropri
manag
background
problem
amen
intervent
recent
publish
consensu
statement
sever
asthma
broaden
concept
difficult
asthma
reflect
situat
less
develop
countri
access
medic
appropri
care
major
issu
defin
three
differ
patient
group
includ
un
der
treat
symptomat
patient
patient
low
treatment
adher
unconvent
therapi
remain
symptomat
despit
high
dose
therapi
nonadher
prescrib
medic
identifi
number
studi
develop
countri
common
clinic
problem
amongst
adult
children
asthma
includ
asthma
appropri
assess
adher
potenti
modifi
factor
passiv
activ
smoke
ongo
allergen
exposur
psychosoci
factor
etc
prioriti
clinic
assess
patient
asthma
decis
increas
treatment
made
includ
possibl
prescript
expens
biolog
therapi
clinic
divers
underli
pathophysiolog
sever
asthma
need
character
ration
therapeut
target
identifi
relev
biomark
valid
addit
need
control
well
nonintervent
studi
patient
popul
although
inhal
corticosteroid
may
protect
asthma
exacerb
due
allergen
exposur
report
rel
ineffect
children
viru
wheez
suggest
exist
differ
type
childhood
asthma
differ
underli
pathophysiolog
recent
joint
model
longitudin
observ
wheez
parent
report
medic
record
identifi
novel
phenotyp
persist
troublesom
wheez
high
rate
sever
asthma
exacerb
healthcar
util
despit
phenotyp
marker
commonli
consid
indic
good
therapeut
respons
atopi
eczema
children
rel
poor
respons
current
avail
treatment
phenotyp
children
high
risk
asthma
exacerb
recent
identifi
bayesian
infer
two
birth
cohort
studi
multipl
skin
ige
test
collect
throughout
childhood
analysi
reveal
sever
differ
atop
vulner
one
much
higher
risk
asthma
exacerb
howev
group
children
signific
risk
asthma
exacerb
identifi
use
longitudin
data
biomark
allow
identif
clinic
practic
still
lack
sever
attempt
made
identifi
predictor
asthma
exacerb
sever
comorbid
associ
recurr
asthma
exacerb
identifi
adult
patient
includ
sever
nasal
sinu
diseas
reflux
diseas
recurr
respiratori
infect
psycholog
dysfunct
obstruct
sleep
apnoea
psycholog
dysfunct
treatment
nonadher
separ
psychosoci
factor
may
significantli
contribut
risk
asthma
exacerb
signific
number
patient
high
rate
asthma
exacerb
increas
airway
eosinophilia
found
low
percept
lung
dysfunct
asthma
exacerb
frequent
asthma
patient
poor
treatment
adher
poor
adher
remain
one
major
challeng
treatment
sever
asthma
basi
asthma
treatment
guidelin
use
clinic
symptom
impair
lung
function
guid
treatment
airway
inflamm
howev
strong
rational
use
direct
measur
airway
inflamm
addit
mean
guid
treatment
sever
asthma
green
et
al
report
titrat
treatment
sputum
eosinophil
count
success
reduc
asthma
exacerb
treatment
accord
guidelin
confirm
larger
multicentr
studi
also
report
frequenc
sever
eosinophil
exacerb
reduc
without
increas
dose
inhal
corticosteroid
ic
sever
frequenc
noneosinophil
exacerb
also
reduc
treatment
strategi
author
treat
patient
sputum
eosinophil
count
minim
ic
dose
requir
reduc
sputum
eosinophil
count
normal
ii
consid
treatment
option
patient
normal
sputum
eosinophil
count
treatment
airway
obstruct
laba
leukotrien
receptor
antagonist
treatment
neutrophil
inflamm
antibiot
interest
treatment
approach
aim
specif
reduc
airway
eosinophil
use
monoclon
antibodi
direct
interleukin
il
reduc
risk
asthma
exacerb
patient
sever
asthma
persist
airway
eosinophilia
howev
note
even
use
target
approach
approxim
sever
exacerb
remain
unaffect
treatment
attempt
identifi
clinic
biomark
predict
risk
asthma
exacerb
far
fail
howev
small
studi
identifi
possibl
candid
biomark
exampl
gelb
et
al
evalu
use
spirometri
exhal
nitric
oxid
feno
predict
risk
asthma
exacerb
stabl
patient
asthma
month
patient
baselin
predict
plu
feno
ppb
probabl
asthma
exacerb
month
predict
plu
feno
ppb
zero
probabl
asthma
exacerb
period
feno
paramet
may
robust
measur
degre
eosinophil
airway
inflamm
numer
epidemiolog
studi
indic
asthma
exacerb
associ
upper
respiratori
viral
infect
mostli
rhinovirus
lesser
degre
respiratori
syncyti
viru
coronaviru
frequenc
estim
childhood
adult
asthma
respect
confirm
systemat
review
review
data
publish
epidemiolog
studi
data
childhood
asthma
extens
adult
asthma
reveal
absenc
geograph
influenc
review
indic
high
rate
respiratori
bacteri
infect
also
associ
asthma
exacerb
data
inconsist
howev
bisgaard
et
al
provid
evid
bacteri
infect
viral
infect
independ
associ
wheez
episod
infant
year
old
odd
ratio
respect
although
confirmatori
studi
need
perform
current
data
strongli
suggest
respiratori
infect
major
caus
asthma
exacerb
studi
reveal
synerg
viral
infect
allergen
exposur
increas
risk
asthma
exacerb
requir
hospit
children
adult
atop
asthmat
patient
sever
prolong
lower
respiratori
tract
symptom
rhinoviru
infect
nonatop
healthi
control
may
explain
impair
innat
acquir
immun
airway
asthma
indic
studi
experiment
clinic
viral
infect
impair
airway
immun
correl
vivo
sever
infect
viral
load
consequ
specif
nonspecif
antivir
strategi
may
great
potenti
therapeut
prevent
strategi
asthma
exacerb
hypothesi
support
preliminari
clinic
studi
patient
asthma
also
defici
type
iii
interferon
respons
bacteri
stimuli
suggest
inadequ
host
defenc
mechan
mechan
specif
infecti
agent
underli
factor
increas
suscept
rhinoviru
enteroviru
infect
like
caus
asthma
exacerb
virus
patient
age
except
rsv
infant
viru
load
viru
rate
correl
symptom
sever
studi
indic
asthma
subject
greater
risk
invas
pneumococc
infect
patient
without
asthma
report
or
rang
exampl
studi
klemet
colleagu
assess
risk
invas
pneumococc
streptococcu
pneumonia
infect
ipi
amongst
adult
patient
asthma
use
nation
laboratori
surveil
case
ipi
select
patient
age
year
thu
larg
exclud
copd
patient
along
noninfect
control
per
ipi
case
match
age
sex
health
district
asthma
case
categor
high
hospit
within
previou
month
low
risk
prescript
drug
entitl
hospit
within
previou
month
overal
case
asthma
asthma
respect
vs
control
asthma
respect
indic
adult
work
age
asthma
substanti
increas
risk
ipi
impair
immun
respons
may
associ
exacerb
asthmat
children
reduc
lung
function
normal
lung
function
specif
time
asthma
exacerb
lower
express
respons
gene
observ
children
reduc
lung
function
children
normal
lung
function
studi
shown
genet
factor
vitamin
particul
matter
modifi
effect
environment
exposur
exacerb
frequenc
advent
genomewid
associ
studi
popul
sever
asthma
asthma
exacerb
may
aid
better
predict
exacerb
phenotyp
subclassif
patient
subphenotyp
may
reflect
differ
aetiopathogenesi
respons
treatment
allow
better
target
treatment
childhood
asthma
guidelin
outlin
stepwis
treatment
escal
increas
diseas
sever
impair
symptom
control
fail
adequ
deal
nonrespond
particular
stepwis
treatment
appear
alway
appropri
children
younger
year
particularli
mainli
asthma
often
respond
inhal
corticosteroid
sever
asthma
children
complex
asthma
phenotyp
chang
develop
requir
continu
reassess
make
analys
childhood
asthma
less
use
appar
phenotyp
stabil
within
popul
obscur
signific
individu
instabl
diseas
express
one
characterist
sever
asthma
childhood
larg
size
skin
test
wheal
inhal
food
allergen
furthermor
patient
group
result
skin
test
ige
measur
individu
allergen
alway
concord
consequ
test
carri
quantifi
similar
quantit
relationship
skin
test
sige
level
also
report
relat
sever
airway
adult
rhinoviru
infect
infant
induc
wheez
longitudin
studi
shown
significantli
associ
develop
childhood
asthma
anoth
prospect
studi
teenag
asthma
strongli
associ
infant
wheez
requir
hospit
studi
identifi
eczema
ige
earli
factor
risk
develop
teenag
asthma
increas
fivefold
respiratori
syncyti
wheez
infant
wheez
rhinovirus
frequent
found
lower
airway
infant
recurr
respiratori
symptom
major
infant
exhibit
increas
airway
resist
infant
wheez
requir
hospit
sole
rhinoviru
infect
sole
infect
common
airway
virus
associ
atopi
recent
studi
demonstr
cardin
featur
bronchial
epitheli
cell
children
sever
asthma
impair
induct
rhinoviru
although
patient
group
highli
atop
relationship
observ
atopi
allergi
inflamm
impair
interferon
longitudin
studi
unselect
birth
cohort
monitor
lung
function
age
year
report
persist
wheez
start
earli
life
associ
declin
lung
function
adult
life
increas
risk
exacerb
declin
lung
function
also
associ
sever
asthma
exacerb
adult
asthma
german
birth
cohort
children
show
risk
develop
persist
asthma
age
year
significantli
increas
earli
allergen
sensit
combin
exposur
high
level
perenni
allergen
earli
life
recent
studi
predictor
subsequ
troublesom
symptom
amongst
children
wheez
larg
skin
test
respons
allergen
histori
previou
exacerb
eczema
attempt
identifi
phenotyp
adult
asthma
includ
use
unsupervis
cluster
analys
aim
group
patient
share
key
featur
asthma
airway
inflammatori
diseas
haldar
colleagu
group
patient
accord
clinic
symptom
evid
airway
inflamm
base
sputum
eosinophil
count
found
treatment
airway
inflamm
appropri
patient
mild
moder
asthma
fail
sever
form
identifi
two
discord
group
patient
refractori
standard
treatment
approach
repres
patient
one
discord
group
patient
character
obes
noneosinophil
phenotyp
group
asthma
symptom
high
degre
airway
inflamm
use
asthma
treatment
two
discord
group
would
lead
overtreat
former
undertreat
latter
group
one
difficulti
attempt
use
cluster
techniqu
defin
diseas
mechan
defin
caus
effect
word
pathophysiolog
featur
consequ
underli
caus
diseas
confound
factor
influenc
treatment
lack
nonadher
defin
group
patient
chronic
diseas
accord
differ
person
trait
identifi
person
trait
govern
treatment
adher
signific
overlap
phenotyp
identifi
haldar
et
al
identifi
moor
et
al
similar
initi
includ
unbias
biomark
predict
respiratori
diseas
outcom
consortium
publish
systemat
algorithm
approach
differenti
problemat
difficult
sever
refractori
asthma
evalu
patient
chronic
sever
asthma
symptom
use
clinic
research
special
care
publish
practal
consensu
report
endotyp
attempt
assign
patient
asthma
group
share
specif
pathophysiolog
featur
aim
identifi
basi
ration
treatment
heterogen
group
patient
sever
asthma
found
group
three
recogniz
clinic
phenotyp
sever
asthma
emerg
variou
analyt
studi
see
tabl
sever
atop
form
ii
sever
intrins
asthma
malign
sever
asthma
phenotyp
iii
sever
asthma
obes
howev
emphas
distinct
pathophysiolog
mechan
underpin
differ
clinic
phenotyp
sever
asthma
yet
identifi
one
potenti
problem
approach
unbias
cluster
analysi
includ
import
dimens
time
may
essenti
take
account
potenti
crucial
longitudin
chang
furthermor
unsupervis
learn
may
use
tool
gener
new
hypothes
use
techniqu
find
associ
predefin
outcom
sever
asthma
mislead
asthma
sever
deriv
use
variabl
use
cluster
mount
evid
demonstr
close
associ
sensitis
fungi
asthma
sever
term
sever
asthma
fungal
sensit
saf
propos
patient
persist
sever
asthma
fungal
sensit
pilot
studi
suggest
improv
asthma
antifung
treatment
patient
group
sever
studi
shown
standard
guidelin
treatment
persist
asthma
ic
provid
variabl
respons
asthmat
subject
show
littl
improv
andor
bronchial
gain
optim
asthma
control
goal
studi
bateman
colleagu
use
year
increas
dose
combin
ic
laba
treatment
patient
persist
asthma
report
patient
vari
degre
diseas
sever
achiev
asthma
asthma
exacerb
risk
may
reduc
use
medic
ie
inhal
combin
agonist
corticosteroid
control
reliev
diseas
price
trial
aim
identifi
predictor
week
respons
ic
although
sever
baselin
biomark
asthma
symptom
correl
improv
greater
bronchodil
revers
show
strong
p
correl
differenti
respond
improv
nonrespond
improv
reveal
asthma
control
respond
maintain
continu
ic
nonrespond
improv
observ
without
ic
interestingli
tiotropium
antimuscarin
agent
still
approv
copd
recent
shown
improv
lung
function
patient
sever
uncontrol
asthma
four
clinic
phenotyp
sever
asthma
describ
tabl
sever
atop
form
partial
respond
standard
treatment
tabl
indic
possibl
treatment
approach
two
group
patient
sever
asthma
describ
haldar
et
al
less
respons
standard
treatment
treatment
option
patient
sever
asthma
remain
symptomat
despit
adher
standard
medic
care
includ
novel
drug
shown
preliminari
studi
effect
treat
airway
inflamm
asthma
warrant
investig
novel
approach
bronchial
thermoplasti
import
note
effect
use
novel
treatment
option
better
understand
pathophysiolog
inflammatori
mechan
sever
asthma
subtyp
requir
order
studi
delin
specif
respons
pattern
previous
note
antifung
treatment
may
benefit
patient
sever
asthma
fungal
sensit
larg
studi
need
support
initi
find
current
treatment
asthma
exacerb
inadequ
new
approach
treatment
need
may
includ
treatment
treatment
aim
boost
defici
antivir
immun
respons
andor
specif
antivir
treatment
may
patient
sever
asthma
could
benefit
treatment
target
neutrophil
inflamm
without
suppress
immun
anoth
question
need
address
possibl
benefit
asthma
exacerb
antibacteri
treatment
wide
use
despit
recommend
guidelin
advanc
molecular
biolog
immunolog
use
develop
novel
biolog
drug
asthma
treatment
includ
therapeut
antibodi
solubl
receptor
cytokin
small
molecul
combin
thereof
target
differ
effector
molecul
influenc
underli
immun
inflammatori
process
biolog
drug
current
clinic
trial
asthma
howev
major
difficulti
develop
novel
drug
treat
asthma
includ
complex
diseas
term
differ
diseas
phenotyp
underli
molecular
mechan
ii
limit
number
biomark
identifi
diseas
classif
iii
effect
current
standard
treatment
approach
combin
inhal
steroid
agonist
effect
cheap
make
compar
improv
difficult
identifi
multicentr
clinic
trial
iv
low
patient
adher
characterist
treatment
chronic
diseas
v
preclin
anim
model
may
poorli
predict
clinic
efficaci
importantli
futur
clinic
trial
need
identifi
patient
group
respond
novel
treatment
provid
evid
stratifi
person
approach
asthma
manag
primari
care
recognit
clinic
heterogen
asthma
exist
differ
form
sever
asthma
obscur
number
gener
defici
includ
limit
avail
time
clinic
resourc
lack
capac
clinic
capabl
nonguidelin
treatment
asthma
high
provis
treatment
patient
asthma
vari
greatli
exampl
use
ic
across
european
countri
influenc
comorbid
asthma
exacerb
asthma
symptom
children
adult
suffici
recogn
patient
asthma
primari
care
found
uncontrol
diseas
furthermor
becom
increasingli
clear
mani
patient
diagnos
asthmat
even
full
evalu
tertiari
centr
asthma
variou
diagnos
indic
fundament
need
establish
improv
diagnosi
basi
appropri
manag
resourc
need
review
patient
frequent
diseas
control
achiev
vari
healthcar
system
finnish
nation
asthma
programm
predic
systemat
approach
diseas
manag
underpin
educ
skill
train
primari
care
demonstr
invest
structur
health
system
deliv
asthma
care
reduc
morbid
significantli
lower
overal
cost
discuss
aim
highlight
promin
issu
attempt
acquir
better
understand
asthma
exacerb
sever
asthma
howev
sever
addit
clinic
pathophysiolog
issu
import
improv
understand
asthma
complex
diseas
highlight
partli
scientif
consensu
exact
relev
howev
two
exampl
briefli
review
airway
remodel
associ
poor
clinic
outcom
amongst
asthmat
patient
pathophysiolog
relev
effect
treatment
airway
remodel
unclear
airway
remodel
featur
adult
asthma
found
similar
extent
quit
earli
children
asthma
use
epitheli
reticular
basement
membran
thicken
marker
airway
remodel
associ
airway
remodel
age
symptom
durat
lung
function
concurr
eosinophil
airway
inflamm
found
albeit
small
number
patient
inflammatori
structur
chang
typic
asthma
airway
eosinophilia
angiogenesi
observ
children
asthma
also
atop
children
without
asthma
rais
possibl
patholog
lesion
may
associ
atopi
even
absenc
asthmat
symptom
reticular
membran
thicken
eosinophil
inflamm
characterist
asthma
older
children
adult
present
wheez
infant
revers
airflow
obstruct
even
presenc
atopi
propos
lack
rbm
thicken
wheezi
infant
due
appar
pauciti
eosinophil
inflamm
may
role
drive
allerg
airway
remodel
base
data
mani
popul
studi
gener
consid
environ
import
influenc
develop
asthma
allerg
diseas
howev
propos
mechan
particularli
role
atopi
underli
effect
environ
asthma
aetiolog
need
revis
light
recent
find
evid
increas
preval
sever
asthma
develop
countri
parallel
declin
sever
develop
countri
interact
environ
asthma
diseas
mechan
complex
genet
variant
protect
one
environ
may
associ
increas
risk
anoth
environ
develop
diagnost
procedur
access
within
primari
care
ensur
correct
diagnosisan
accept
need
iter
review
gain
control
diseas
patient
asthma
fail
becom
control
need
evalu
confirm
asthma
correct
diagnosi
evalu
requiredimprov
tool
score
asthma
patient
term
diseas
sever
futur
risk
need
develop
use
primari
care
futur
studi
aim
establish
whether
serum
ige
feno
induc
sputum
eosinophil
count
valuabl
biomark
sever
asthmat
airway
inflammationnew
biomark
need
predict
sever
asthma
risk
exacerb
respons
treatmentsther
need
object
definit
childhood
asthma
broader
use
lung
function
test
especi
preschool
obtain
uniform
criteria
diagnosi
initi
treatment
control
diseasein
childhood
adult
asthma
express
atopi
vari
time
differ
characterist
way
reveal
differ
underli
pathophysiolog
mechan
includ
sever
phenotyp
observ
longitudin
studi
perform
standard
way
patient
biolog
data
sampl
use
asthma
regist
allow
better
character
epidemiolog
current
healthcar
util
risk
factor
includ
genet
suscept
comorbid
link
exacerb
severityth
futur
task
devis
studi
differenti
patient
phenotyp
use
robust
clinic
relev
biomark
includ
longitudin
outcom
time
exacerb
increas
airway
remodel
identifi
relev
environment
factor
includ
influenc
current
prior
medic
facilit
identif
new
asthma
endotyp
studi
contribut
repositori
biobank
biolog
sampl
asthma
populationfor
character
heterogen
sever
asthma
improv
clinic
studi
need
improv
evid
base
random
control
trial
asthma
includ
highli
select
patient
almost
exclus
healthi
asthmat
reversibilitycohort
studi
may
complement
clinic
trialsther
still
insuffici
longitudin
data
adult
asthma
cohort
studi
age
group
need
establish
improv
primari
care
asthmat
patient
need
urgent
attent
requir
radic
changesth
ideal
approach
deal
asthmat
patient
primari
care
character
patient
ii
confirm
diagnosi
iii
confirm
whether
new
exist
patient
gain
control
iter
applic
structur
review
consid
reduc
treatment
control
achiev
undertak
appropri
monitor
iv
maintain
control
teach
patient
asthma
develop
patient
skill
accord
model
develop
glasziou
v
attempt
understand
patient
perspect
may
key
improv
patient
complianc
vi
consid
risk
exacerb
separ
control
everyday
symptom
factor
may
increas
risk
exacerb
vii
realiz
nonsymptomat
patient
also
risk
exacerbationsth
complex
multifactori
natur
asthma
resourc
limit
primari
care
need
better
character
order
address
wide
variabl
care
deliv
environ
mechan
enabl
readili
access
mean
patient
alreadi
met
vari
degre
success
need
developedprimari
clinician
recogn
research
agenda
need
direct
improv
asthma
care
seen
primari
care
secondari
care
patient
uncontrol
asthma
either
diseas
ii
fulli
compliant
treatment
iii
unabl
appreci
deterior
diseas
iv
physician
underestim
degre
diseas
control
undertr
recogn
effect
comorbid
v
asthma
custov
serv
consult
circassia
receiv
speaker
fee
glaxo
smith
kline
thermo
fisher
scientif
airsonet
novarti
msd
alk
receiv
research
grant
uk
medic
research
council
moulton
charit
foundat
nation
institut
health
research
past
five
year
l
johnston
research
grant
astra
zeneca
centocor
glaxosmithklin
medimmun
synairgen
l
johnston
hold
share
option
synairgen
l
johnston
consult
work
astrazeneca
centocor
glaxosmithklin
medimmun
synairgen
last
five
year
pavord
receiv
speaker
honoraria
speak
sponsor
meet
astra
zeneca
boehring
inglehiem
aerocrin
gsk
receiv
honoraria
attend
advisori
panel
almiral
astra
zeneca
boehring
ingelheim
gsk
msd
novarti
dey
napp
receiv
sponsorship
attend
intern
scientif
meet
boehring
ingelheim
gsk
astra
zeneca
napp
gaga
receiv
research
grant
novarti
bi
cephalon
teva
gsk
l
fabbri
receiv
consult
fee
boehring
ingelheim
chiesi
glaxosmithklin
msd
nycom
pearl
therapeut
sterna
peer
voic
europ
om
pharma
sa
kyorin
pharmaceut
boston
scientif
bayer
read
advisori
board
reimburs
expens
astrazeneca
novarti
roch
deutsch
zentrum
luft
und
raumfahrt
german
aerospac
center
mundipharma
int
genetech
inc
elev
pharmaceut
ferrer
group
nycom
dynamicon
laboratori
guidotti
e
bel
receiv
consult
fee
novarti
gsk
fee
speak
gsk
p
le
receiv
speaker
fee
glaxo
smith
kline
astrazeneca
receiv
research
fund
astrazeneca
pharmanet
ag
receiv
research
grant
nation
health
medic
research
council
australia
australian
research
council
j
last
five
year
consult
andor
given
lectur
gsk
astrazeneca
aerov
novarti
ucb
oriel
merck
receiv
honoraria
also
receiv
research
grant
particip
clinic
trial
novarti
gsk
astrazeneca
actelion
full
organ
univers
gothenburg
p
demoli
consult
speaker
stallergen
alk
circassia
chiesi
speaker
merck
astrazeneca
menarini
glaxosmithklin
c
akdi
serv
scientif
advisori
board
novarti
actellion
circassia
allergopharma
stallergen
receiv
research
grant
novarti
swiss
nation
scienc
foundat
research
grant
ryan
support
attend
confer
provid
consult
servic
lectur
behalf
az
novarti
chiesi
mundipharma
msd
aerocrin
mika
receiv
speaker
fee
menarini
glaxosmithklin
msd
orion
pharma
serv
consult
orion
pharma
receiv
research
grant
sigrid
juseliu
foundat
helsinki
univers
hospit
research
grant
f
martinez
serv
consult
medimmun
receiv
speaker
fee
merck
abbott
receiv
grant
fund
nation
institut
health
p
obyrn
serv
scientif
advisori
board
abbott
astrazeneca
asmacur
boehring
ingelheim
glaxosmithklin
medimmun
merck
receiv
speaker
fee
astrazeneca
boehring
ingelheim
chiesi
glaxosmithklin
nycom
also
receiv
grant
aim
amgen
astrazeneca
genentech
glaxosmithklin
novarti
ono
papi
scientif
advisori
board
receiv
speaker
fee
astrazeneca
chiesi
glaxosmithklin
teva
mundipharma
novarti
bi
almiral
menarini
receiv
research
grant
astrazeneca
chiesi
glaxosmithklin
novarti
bi
univers
ferrara
magnan
serv
consult
novarti
takeda
mundipharma
boehring
receiv
speaker
fee
glaxo
smith
kline
chiesi
novarti
msd
mundipharma
receiv
research
grant
msd
e
hamelmann
serv
consult
boehring
ingelheim
hal
allergi
alk
novarti
receiv
speaker
fee
stallergen
symbiopharm
novarti
alk
receiv
research
grant
german
nation
research
foundat
dfg
german
ministri
educ
research
bmbf
ministri
educ
research
n
g
papadopoulo
receiv
payment
consult
abbvi
novarti
menarini
meda
lectur
novarti
uriach
gsk
allergopharma
stallergen
develop
educ
present
uriach
meda
grant
nestl
msd
gsk
author
paper
declar
conflict
interest
